Oxana Beskrovnaya is the Chief Scientific Officer at Dyne Therapeutics Inc., a biotechnology company focused on developing innovative treatments for genetic diseases. With a robust background in molecular biology and genetics, Beskrovnaya has been instrumental in advancing the company's mission to deliver life-changing therapies to patients. She holds a Ph.D. in Biochemistry from the University of California, San Francisco, where her research centered on understanding the molecular mechanisms of neurodegenerative diseases. Before joining Dyne Therapeutics, Beskrovnaya held significant roles at several leading biotech firms, including Novartis and Biogen, where she led research teams and spearheaded projects that contributed to the development of novel therapeutic approaches. Her expertise in RNA biology and gene therapy has been pivotal in driving Dyne's research and development efforts. At Dyne, Beskrovnaya oversees the scientific strategy and directs the company's pipeline, which includes programs targeting Duchenne muscular dystrophy and myotonic dystrophy. As Chief Scientific Officer, Beskrovnaya plays a crucial role in translating scientific discoveries into clinical applications. Her leadership has been essential in navigating the complex landscape of genetic medicine, ensuring that Dyne remains at the forefront of the industry. Under her guidance, the company has made significant strides in developing its proprietary FORCE™ platform, which aims to enhance the delivery of oligonucleotide therapies to muscle tissues. Beskrovnaya's dedication to scientific excellence and her vision for improving patient outcomes continue to drive Dyne's success in the biopharmaceutical field.